QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
QuidelOrtho Corp
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 7, 2026
$12.76−0.15 (-1.16%)
Close on Oct 19, 2026
- Market cap
- $871.51M
- P/E (TTM)
- –
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Jun 28, 2026
Total debt
$2.89B
$355.70M due within a year
Net debt
$2.77B
After $123.40M of cash
Implied interest rate
6.92%
FY2025 interest ÷ average debt
Interest coverage
-5.2×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in QuidelOrtho's annual report. Trading prices and yields need FINRA TRACE data.